Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/27/2021 | Series C-2 | $15MM | $xx.xx | $1.15B | 8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc | |
Price per Share
$xx.xx
Shares Outstanding
172,800
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
|
||||||
10/27/2021 | Series C-1 | $204.34MM | $xx.xx | $1.15B | 8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc | |
Price per Share
$xx.xx
Shares Outstanding
1,094,753
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexanria Venture Investments, Icon, Koch Disruptive Technologies, Piedmont, Talos Vc
|
||||||
02/11/2021 | Series B-2 | $2.99MM | $xx.xx | $240.97MM | Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures | |
Price per Share
$xx.xx
Shares Outstanding
73,326
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
|
||||||
02/11/2021 | Series B-1 | $55.66MM | $xx.xx | $240.97MM | Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures | |
Price per Share
$xx.xx
Shares Outstanding
1,088,327
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital Management, Dexcel Pharma, Duquesne Family, Schusterman Foundation, Tlv Partners, Viola Ventures
|
||||||
05/14/2020 | Series Seed-1 | $214,992.12 | $xx.xx | $38.16MM | Tlv Partners, Viola Ventures | |
Price per Share
$xx.xx
Shares Outstanding
36,390
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Tlv Partners, Viola Ventures
|
||||||
05/14/2020 | Series Seed-2 | $5.3MM | $xx.xx | $38.16MM | Tlv Partners, Viola Ventures | |
Price per Share
$xx.xx
Shares Outstanding
672,817
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Tlv Partners, Viola Ventures
|
||||||
05/14/2020 | Series A | $12.05MM | $xx.xx | $38.16MM | Tlv Partners, Viola Ventures | |
Price per Share
$xx.xx
Shares Outstanding
956,259
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Tlv Partners, Viola Ventures
|